Artisan Partners’s UroGen Pharma URGN Stock Holding History

Artisan Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-460,970	Closed	-$8.89M	–	366
2020 Q3	$8.89M	Buy	460,970 +99,171	+27%	+$2.25M	0.01%	305
2020 Q2	$9.45M	Buy	361,799 +55,374	+18%	+$1.35M	0.02%	289
2020 Q1	$5.47M	Buy	+306,425	New	+$8.28M	0.01%	287

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Artisan Partners's URGN Position: Q4 2020 in Review

Artisan Partners sold out of UroGen Pharma (URGN) in Q4 2020, closing a stake of 460,970 shares — an estimated $8.89M sold.

Artisan Partners first reported a position in URGN in Q1 2020 and held it in 3 quarters. The position peaked at $9.45M in Q2 2020. 81 funds tracked by Wall St. Rank hold URGN as of Q4 2020.

Artisan Partners reported no remaining UroGen Pharma position as of Q4 2020 after selling out during the quarter.
Artisan Partners sold 460,970 UroGen Pharma shares in Q4 2020, an estimated $8.89M.
Artisan Partners first reported a position in UroGen Pharma in Q1 2020 and held it in 3 quarters.
Artisan Partners's UroGen Pharma position peaked at $9.45M in Q2 2020.
81 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2020.

Based on Artisan Partners's 13F filing for Q4 2020, filed 10 Feb 2021.